Pancreatic Cancer Research

ResearcherNorth Dakota State UniversityActive in the last 2 years

Paras Mani Giri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-2039-4864; OpenAlex author ID A5066313249. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 4

  1. Mesenchymal Stem Cell Exosome-Mediated Delivery of Paclitaxel for Pancreatic Cancer Therapy. Co-author DOI 10.3390/biom16020269↗
  2. Panobinostat-Loaded Albumin Nanoparticles for the Treatment of Pancreatic Cancer. Co-author DOI 10.1016/j.jddst.2025.107341↗
  3. Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic cancer. Co-author DOI 10.1016/j.biopha.2024.116743↗
  4. Mesenchymal stem cell-delivered paclitaxel nanoparticles exhibit enhanced efficacy against a syngeneic orthotopic mouse model of pancreatic cancer. Co-author DOI 10.1016/j.ijpharm.2024.124753↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Buddhadev Layek · 4 shared papers, 2024–2026 · strength 1.22
  2. Anurag Banerjee · 2 shared papers, 2024–2026 · strength 0.61
  3. Philip Salu · 2 shared papers, 2024 · strength 0.50
  4. Katie M. Reindl · 2 shared papers, 2024 · strength 0.50
  5. Yongki Choi · 1 shared paper, 2026 · strength 0.36
  6. Sanku Mallik · 1 shared paper, 2024 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.